Global Erythropoietin Drugs Market Market Trends
Rising rates of anemia and related illnesses
Growing rates of anemia, cancer, chronic renal disease, bone marrow failure, and HIV are some of the main factors propelling the market for erythropoietin-containing medications. Data from the National Center for Biotechnology Information show that darbepoetin alfa and epoetin alfa were the medicines approved by the European medical agency and used in the United States of America (US) to treat chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies. Furthermore, the market for erythropoietin-containing medications is driven by the growing prevalence of iron, vitamin B12, and folic acid deficiencies brought on by desk-bound lifestyles.
During operations, blood transfusions
Additionally, the target market is anticipated to be driven by blood transfusions during solid tumor surgeries and treatments, malignant lymphoma or multiple myeloma, and cardiovascular health. Additionally, as more drug patents expire, vendors emphasize the use of biosimilar medications, which provide the same therapeutic effect at a reduced cost. This is another reason supporting the target market's growth. However, extended treatment times and cost-effectiveness in the therapeutic pharmaceutical process are vital issues that limit the market's ability to grow for erythropoietin-based medications.